Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 79
Filter
1.
Eur J Gynaecol Oncol ; 30(6): 616-21, 2009.
Article in English | MEDLINE | ID: mdl-20099489

ABSTRACT

PURPOSE: Role of microRNAs in malignancies is well established due their regulatory role in cellular differentiation, proliferation and cell cycle control. Our purpose was to determine miRNA profiles of serially established ovarian cancer cell lines and the effect of genistein treatment. METHODS: Cell lines (UL-3A, UL-3B) were established from one patient during progression of disease. miRNA profiling was performed in untreated and genistein-treated cells. Estrogen receptors (ER) were studied with real-time polymerase chain reaction (RT-PCR) and Western immunoblotting. In vitro migration and invasion assays were utilized. RESULTS: While 108 miRNAs were expressed equally in both cell lines and their genistein-treated counterparts, an additional 53 miRNAs were differentially expressed. Genistein resulted in induction of ERalpha and ERbeta in ovarian cancer cells. A significant reduction in migration and invasion of UL-3A and UL-3B was demonstrated in genistein-treated cells. CONCLUSION: Common and unique miRNA profiles were demonstrated between the two cell lines, some of which were altered by genistein.


Subject(s)
Genistein/pharmacology , MicroRNAs/drug effects , Ovarian Neoplasms/drug therapy , Protein Kinase Inhibitors/pharmacology , Cell Line, Tumor , Estrogen Receptor alpha/metabolism , Estrogen Receptor beta/metabolism , Female , Humans
2.
Int J Gynecol Cancer ; 17(6): 1278-82, 2007.
Article in English | MEDLINE | ID: mdl-17997796

ABSTRACT

This study addresses whether CD3-zeta suppression associated with cervical intraepithelial neoplasia (CIN) I, II, and III is mediated by a circulating factor and if this suppression is reversed following treatment. Serum was isolated from patients with CIN before and after curative therapy. Jurkat T cells were incubated with patient-derived sera for 4 days, and CD3-zeta expression was analyzed by western immunoblot. Sera from control female volunteers did not suppress CD3-zeta expression of Jurkat cells, while sera from women with CIN I, II, and III suppressed 58.9%, 75.3%, and 80.5%, respectively. Suppression observed in women with CIN I was significantly different from that observed with CIN II and III. Posttreatment zeta suppression was noted to be reversed in women with CIN II and III although the decreased suppression in CIN III patients was not statistically significant. Our study demonstrates that in vivo suppression of zeta chains in patients with CIN can be the result of a circulating factor. In vitro zeta expression increased in patients with CIN II and III after treatment, although the increase was only statistically significant in patients with CIN II.


Subject(s)
CD3 Complex/metabolism , T-Lymphocytes/metabolism , Uterine Cervical Dysplasia/immunology , Uterine Cervical Neoplasms/immunology , Case-Control Studies , Chromatography, Gel , Disease Progression , Female , Gene Expression Regulation, Neoplastic , Humans , Jurkat Cells , Pilot Projects , Treatment Outcome , Uterine Cervical Neoplasms/blood , Uterine Cervical Neoplasms/surgery , Uterine Cervical Dysplasia/blood , Uterine Cervical Dysplasia/surgery
3.
Br J Cancer ; 92(2): 305-11, 2005 Jan 31.
Article in English | MEDLINE | ID: mdl-15655551

ABSTRACT

Dendritic and lymphoid 'exosomes' regulate immune activation. Tumours release membranous material mimicking these 'exosomes,' resulting in deletion of reactive lymphocytes. Tumour-derived 'exosomes' have recently been explored as vaccines, without analysis of their immunologic consequences. This investigation examines the composition of tumour-derived 'exosomes' and their effects on T lymphocytes. Membranous materials were isolated from ascites of ovarian cancer patients (n=6) and Western immunoblotting was performed for markers associated with 'exosomes.' Using cultured T cells, 'exosomes' were evaluated for suppression of CD3-zeta and JAK 3 expressions and induction of apoptosis, measured by DNA fragmentation. 'Exosome' components mediating suppression of CD3-zeta were isolated by continuous eluting electrophoresis and examined by Western immunoblotting. 'Exosomes' were shown to be identical with previously characterised shed membrane vesicles by protein staining and TSG101 expression. 'Exosomes' expressed class I MHC, placental alkaline phosphatase, B23/nucleophosmin, and FasL. 'Exosomes' suppressed expression of T-cell activation signalling components, CD3-zeta and JAK 3 and induced apoptosis. CD3-zeta suppression was mediated by two components: 26 and 42 kDa. Only the 42 kDa component reacted with anti-FasL antibody. These results indicate that, while 'exosomes' express tumour antigens, leading to their proposed utility as tumour vaccines, they also can suppress T-cell signalling molecules and induce apoptosis.


Subject(s)
Cell Membrane/immunology , Cytoplasmic Vesicles/immunology , Ovarian Neoplasms/immunology , Signal Transduction/immunology , T-Lymphocytes/immunology , Antigens, Neoplasm/analysis , Antigens, Neoplasm/immunology , Blotting, Western , CD3 Complex/biosynthesis , Cell Membrane/chemistry , Cells, Cultured , Cytoplasmic Vesicles/chemistry , DNA Fragmentation , Electrophoresis, Polyacrylamide Gel , Female , Histocompatibility Antigens Class I/immunology , Humans , Janus Kinase 3 , Lymphocyte Activation/immunology , Protein-Tyrosine Kinases/biosynthesis
4.
Int J Gynecol Cancer ; 12(6): 715-9, 2002.
Article in English | MEDLINE | ID: mdl-12445248

ABSTRACT

The objective of this study was to determine if there was a relationship between serum vascular endothelial growth factor (VEGF) levels and ovarian malignancies by contrasting a population with ovarian malignancies and a population free of gynecological neoplasms. Two hundred forty four serum samples were obtained from the US National Cancer Institute's Prostate, Lung, Colon, and Ovarian Cancer Screening Project. These samples were analyzed by enzyme-linked immunosorbent assays in duplicate, and on completion of the assays, the samples were decoded for age and disease type. Average VEGF values for the nongynecological control group was 4.399 ng/ml; for benign gynecologic cases, 2.515 ng/ml; and for patients with malignancies, 4.287 ng/ml. Specifically, there was no difference between the mean value of VEGF in patients with ovarian malignancies and the patients with benign gynecological tumors (P = 0.8823). Also, there was no difference between the mean value of VEGF in patients with ovarian malignancies and the control patients who did not have gynecological disease (P = 0.3110). Using the Mann-Whitney U-test, no significant differences were found between the three populations of this study. Based on our data, due to the lack of significant difference in mean serum VEGF values between patients with and without ovarian malignancies, we feel that serum VEGF cannot be used as a possible screening tool for ovarian cancer.


Subject(s)
Biomarkers, Tumor/blood , Endothelial Growth Factors/blood , Intercellular Signaling Peptides and Proteins/blood , Lymphokines/blood , Ovarian Neoplasms/blood , Adenocarcinoma/blood , Adenocarcinoma/pathology , Adult , Aged , Carcinoma, Squamous Cell/blood , Carcinoma, Squamous Cell/pathology , Case-Control Studies , Cystadenocarcinoma, Papillary/blood , Cystadenocarcinoma, Papillary/pathology , Female , Humans , Middle Aged , Ovarian Diseases/blood , Ovarian Diseases/pathology , Ovarian Neoplasms/pathology , Predictive Value of Tests , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
5.
Anticancer Res ; 21(4A): 2761-8, 2001.
Article in English | MEDLINE | ID: mdl-11724352

ABSTRACT

BACKGROUND: Drug sensitivity testing (DST) is used to predict the clinical response to chemotherapy with limited success. Our objective was to evaluate assays that measure cell proliferation or apoptosis in determining sensitivity of ovarian cancer cells to cisplatin and paclitaxel. MATERIALS AND METHODS: Four ovarian cancer lines were used. LD10-LD90 doses were determined by viability assays. Assays measuring cell proliferation, sulforhodamine-B (SRB), tritiated thymidine; and cell death, diphenylamine or DNA histone ELISA were compared. RESULTS: SRB assay was consistent and sensitive. Histone ELISA correlated with the viability assay at high doses. The [3H] thymidine test was not sensitive and resulted in false positive responses. While less sensitive, detection of apoptosis by diphenylamine assay shows a similar trend to histone ELISA. CONCLUSIONS: We demonstrate significant differences between the various assays. Most of these assays are better predictors of resistance. Further studies are needed to determine the best correlation between in vitro testing and responses in vivo.


Subject(s)
Apoptosis/drug effects , Drug Screening Assays, Antitumor/methods , Ovarian Neoplasms/drug therapy , Antineoplastic Agents/pharmacology , Cell Division/drug effects , Cisplatin/pharmacology , DNA Fragmentation , DNA, Neoplasm/biosynthesis , Diphenylamine/analysis , Enzyme-Linked Immunosorbent Assay , Female , Fluorescent Dyes , Humans , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Paclitaxel/pharmacology , Rhodamines , Thymidine/analysis , Thymidine/metabolism
6.
Am J Obstet Gynecol ; 185(4): 812-8, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11641657

ABSTRACT

OBJECTIVE: To investigate TCR-CD3zeta expression by cultured T lymphocytes exposed to midtrimester sera from pregnant women in whom preeclampsia developed at term compared with normotensive pregnant control subjects. STUDY DESIGN: Sera obtained at 24 to 28 weeks' gestation from 16 nulliparous women in whom preeclampsia developed at term and from 32 gestational age-matched control subjects without preeclampsia were evaluated for TCR-CD3zeta chain expression with use of Jurkat cells. Subsets of serum samples from 6 women with preeclampsia and 6 control subjects were then evaluated for their ability to induce apoptosis and to suppress interleukin-2 production. Groups were compared by use of the Kruskal-Wallis test, and P <.05 was considered significant. RESULTS: TCR-CD3zeta chain expression in cultured T lymphocytes was suppressed in approximately 60% of untreated control subjects after incubation with sera from normotensive pregnant women compared with 30% after incubation with sera from women with preeclampsia (P <.001). T-cell apoptosis was significantly higher after incubation with sera from normotensive control subjects, as was the expression of the proapoptotic regulator Bax, compared with sera from women with preeclampsia. Interleukin-2 levels were higher in T cells incubated with sera from women in whom preeclampsia later developed compared with sera from normotensive pregnant women (27.7 ng/mL versus 72.5 ng/mL; P <.001). CONCLUSIONS: Nulliparous women in whom preeclampsia developed did not suppress TCR-CD3zeta levels to the extent of normotensive control subjects, which may be linked to decreased lymphocyte apoptosis. This occurs remotely from the manifestation of clinical disease and suggests a deficiency in a serum factor in preeclampsia that may induce T cell zeta chain suppression in normal pregnancy.


Subject(s)
CD3 Complex/metabolism , Pre-Eclampsia/immunology , Pregnancy Outcome , Pregnancy/blood , Receptors, Antigen, T-Cell/metabolism , T-Lymphocytes/immunology , Adult , Apoptosis/immunology , CD3 Complex/immunology , Case-Control Studies , Cohort Studies , Down-Regulation , Enzyme-Linked Immunosorbent Assay , Female , Gestational Age , Humans , Immunity, Cellular/physiology , Jurkat Cells/immunology , Pre-Eclampsia/diagnosis , Probability , Receptors, Antigen, T-Cell/immunology , Reference Values , Sensitivity and Specificity
7.
Am J Vet Res ; 62(9): 1393-8, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11560266

ABSTRACT

OBJECTIVES: To compare limb-load distribution between horses with and without acute or chronic laminitis. ANIMALS: 10 horses with carbohydrate-induced acute laminitis, 20 horses with naturally occurring chronic laminitis, and 20 horses without foot abnormalities (controls). PROCEDURES: Limb-load distribution was determined, using a custom-designed system that allowed simultaneous quantification of the mean percentage of body weight voluntarily placed on each limb (ie, mean limb load) and the SD of the mean load over a 5-minute period (ie, load distribution profile [LDP]). Load distribution profile was used as an index of frequency of load redistribution. RESULTS: Mean loads on fore- and hind limbs in control horses were 58 and 42%, respectively, and loads were equally and normally distributed between left and right limbs. In addition, forelimb LDP was greater, compared with hind limbs, and was affected by head and neck movement. In comparison, limb-load distribution in horses with chronic laminitis was characterized by an increase in the preferential loading of a forelimb, a decrease in total forelimb load, and an increase in LDP that was correlated with severity of lameness. In horses with carbohydrate-induced acute laminitis, mean limb loads after onset of lameness were not different from those prior to lameness; however, LDP was significantly decreased after onset of lameness. CONCLUSION AND CLINICAL RELEVANCE: Quantification of limb-load distribution may be an applicable screening method for detecting acute laminitis, grading severity of lameness, and monitoring rehabilitation of horses with chronic laminitis.


Subject(s)
Foot Diseases/veterinary , Horse Diseases/physiopathology , Animals , Female , Foot Diseases/physiopathology , Forelimb/physiopathology , Hindlimb/physiopathology , Horses , Lameness, Animal/physiopathology , Male , Statistics, Nonparametric
8.
Int J Oncol ; 19(2): 387-94, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11445857

ABSTRACT

We analyzed clonal populations of ovarian cancer cells for heterogeneity in p53 mutations (exons 4-9) and chemosensitivity. UL-3A cells were developed from a patient with stage IIIC ovarian adenocarcinoma. Heterogeneity in p53 mutations was demonstrated, ranging from point mutations to deletions in exons 4, 6 and 7. UL-3A cells contained two point mutations, in codon 248 of exon 7 and in codon 76 of exon 4. Five groups of clones were identified according to the p53 mutations. UL-3A clones with low p53 levels were more sensitive to CDDP (LD50 <8.0 microg/ml). Heterogeneity of p53 mutations may provide growth advantage during disease progression or chemotherapy.


Subject(s)
Ovarian Neoplasms/pathology , Tumor Suppressor Protein p53/genetics , Antineoplastic Agents/pharmacology , Cisplatin/pharmacology , Clone Cells , DNA Mutational Analysis , DNA, Neoplasm/chemistry , DNA, Neoplasm/genetics , Female , Genetic Heterogeneity , Humans , Immunoblotting , Lethal Dose 50 , Mutation , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/genetics , Paclitaxel/pharmacology , Polymorphism, Single-Stranded Conformational , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Topotecan/pharmacology , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolism , Tumor Suppressor Protein p53/metabolism , bcl-2-Associated X Protein
9.
Br J Cancer ; 84(12): 1624-9, 2001 Jun 15.
Article in English | MEDLINE | ID: mdl-11401315

ABSTRACT

In women with ovarian cancer, suppression of components of the immune system may promote tumour development. Previous studies in ovarian cancer have demonstrated that decreased expression and function of the T-cell receptor (TcR)-associated signal transducing zeta-chain correlates with deficient immune responsiveness of T cells. In this study, sera and ascitic fluids obtained from woman with advanced ovarian cancer were found to suppress the expression of TcR-associated zeta chain. This suppression of zeta chain expression was dose-dependent and was not observed with biologic fluids obtained from healthy women. The factor responsible for the loss of zeta chain was purified from ascites and characterized as a protein with an appropriate molecular weight of 14 kD. Suppression of T-cell TcR-zeta was specific, since neither lck nor ZAP-70 expression was affected, while zeta chain was almost completely suppressed. This selective suppression of TcR-zeta expression by the 14 kD ascites-derived factor was shown to operate at the mRNA level. By defining the mechanism through which this protein modulates TcR-zeta chain levels, it might be possible to ultimately prevent the suppressive influences of the tumour microenvironment and restor immune competence in patients with ovarian carcinoma.


Subject(s)
Carcinoma/pathology , Immunosuppression Therapy , Membrane Proteins/biosynthesis , Ovarian Neoplasms/pathology , Receptor-CD3 Complex, Antigen, T-Cell/biosynthesis , Receptors, Antigen, T-Cell/biosynthesis , Adult , Ascites , Blotting, Western , Carcinoma/genetics , Case-Control Studies , Female , Gene Expression Regulation, Neoplastic , Humans , Immunocompetence , Ovarian Neoplasms/genetics , Proteins/chemistry , Proteins/isolation & purification , Proteins/pharmacology
10.
Gynecol Oncol ; 81(2): 138-43, 2001 May.
Article in English | MEDLINE | ID: mdl-11330940

ABSTRACT

OBJECTIVE: This study analyzed a model for the identification of specific epitopes recognized by autologous tumor-reactive humoral responses of endometrial cancer patients as potential markers for the monitoring of cancer. METHODS: The presence of circulating pro- and mature forms of cathepsin D and antibodies reactive with this enzyme were identified by Western immunoblot and quantitated by an enzyme immunoassay. Specific immunoreactivities with 34- and 52-kDa cathepsin D forms were analyzed by Western immunoblot using sera from endometrial cancer patients (n = 40) and normal volunteers (n = 15). Subsequently, reactivities with specific cathepsin D epitopes were defined by a peptide-specific ELISA. RESULTS: Circulating pro-forms of cathepsin D were detected in 31 of 40 endometrial cancer patients tested and none of the control volunteers. Circulating IgG reactive with cathepsin D could be demonstrated in 29/31 patients with circulating procathepsin D, while an anti-cathepsin D response was not detectable in normal controls. This response appeared to be directed against the pro-peptide portion of cathepsin D. Using a peptide-specific ELISA, the frequencies of antibody production against specific epitopes within the pro-peptide were defined. CONCLUSION: There is a demonstrable tumor-reactive immune response elicited in endometrial cancer patients, directed against specific antigenic epitopes, some of which are conserved among these patients. Since these proteins are recognized as non-self, due at least in part to posttranslational processing errors, defining these epitopes will be useful as a means of diagnosis, assessment of therapeutic success, and, ultimately, identification of immunotherapeutic targets.


Subject(s)
Antibodies, Neoplasm/immunology , Autoantibodies/immunology , Cathepsin D/immunology , Endometrial Neoplasms/immunology , Epitopes/immunology , Amino Acid Sequence , Autoantibodies/blood , Cathepsin D/blood , Endometrial Neoplasms/blood , Enzyme Precursors/blood , Enzyme Precursors/immunology , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoglobulin G/immunology , Molecular Sequence Data
11.
Gynecol Oncol ; 81(1): 71-6, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11277653

ABSTRACT

OBJECTIVES: Cancer patients generally exhibit circulating tumor-reactive immunoglobulins; however, these antibodies fail to eradicate tumors or prevent their progression. This study identifies and characterizes an aberrant tumor-reactive IgG population present in women with ovarian cancer. METHODS: In this pilot study, IgG was isolated from the sera of women with advanced-stage ovarian cancer (stages III and IV, n = 62) and age-matched female volunteers (n = 50) by affinity chromatography. These IgGs were characterized on the basis on their aberrant binding to concanavalin A affinity columns. Subsequently, the concanavalin A-binding moiety was localized following IgG fragmentation, analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and characterized by oligosaccharide profiling. RESULTS: The level of concanavalin A-binding IgG in our control population was 8.9 +/- 2.9%, whereas in ovarian cancer patients, the level of concanavalin A-binding IgG was 38.8 +/- 7.4%. In the patients with ovarian cancer, 87.5 +/- 5.7% of the tumor-reactive IgG was demonstrated to be concanavalin A-binding. Based on oligosaccharide profiling of the fragmented concanavalin A-binding IgG, the aberrant lectin binding appeared to be the consequence of altered glycosylation of one of the two Fc chains. CONCLUSIONS: While our previous studies have identified the presence of circulating IgG reactive with specific tumor-associated antigens and its association with poor prognosis, this report demonstrated the presence of an aberrantly glycosylated IgG population in cancer patients. This altered IgG appeared to be the primary class of tumor-reactive antibodies in these women.


Subject(s)
Antibodies, Neoplasm/blood , Immunoglobulin G/blood , Neoplastic Cells, Circulating/immunology , Ovarian Neoplasms/immunology , Antibodies, Neoplasm/immunology , Antigens, Neoplasm/immunology , Chromatography, Affinity , Concanavalin A/immunology , Concanavalin A/metabolism , Female , Humans , Immunoglobulin G/immunology , Immunoglobulin G/isolation & purification , Middle Aged , Oligosaccharides/immunology , Oligosaccharides/metabolism , Ovarian Neoplasms/blood , Ovarian Neoplasms/pathology , Pilot Projects , Receptors, Concanavalin A/immunology , Receptors, Concanavalin A/metabolism
12.
Fertil Steril ; 73(2): 305-13, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10685534

ABSTRACT

OBJECTIVE: To investigate the reactivity of maternal antibodies with endometrium-derived antigens and to correlate their association with recurrent pregnancy loss (RPL). DESIGN: Prevalence study. SETTING: Academic research center. PATIENT(S): Nulliparous women (n = 10), women with RPL (n = 15), pregnant women (n = 8), and multiparous women with a normal obstetric history (n = 20). INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Reactive antibodies were analyzed by Western immunoblot techniques and quantitated by densitometry. RESULT(S): Antibodies from women with RPL and multiparous women recognized antigens ranging from 10-120 kd on normal endometrium and endometrial tumors. Antibodies from most women with RPL (10/15) and from multiparous women (15/20) recognized 65-kd and 80-kd proteins in normal endometrium. Antibodies from women with RPL recognized 21-kd and 28-kd antigens (12/15 and 13/15, respectively) in endometrial tumors at a significantly greater rate (than did antibodies from multiparous women (5/20 and 8/20, respectively). Women with RPL had significantly lower levels of asymmetric IgG compared with controls. CONCLUSION(S): Recurrent pregnancy loss may be linked with the failure to elicit asymmetric IgG and a unique immunologic recognition of endometrial antigens.


Subject(s)
Abortion, Habitual/immunology , Antibodies/blood , Endometrium/immunology , Adult , Antigens/analysis , Autoantibodies/immunology , Endometrial Neoplasms/immunology , Female , Humans , Immune Sera , Immunoglobulin G/blood , Pregnancy , Reference Values
13.
Diagn Cytopathol ; 21(5): 355-8, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10527485

ABSTRACT

Primary screening devices for cervical cytology must show performance data for the detection of infectious organisms and benign cellular changes (BCC) for cytologists who routinely report these findings. The data on infection and BCC from the AutoPap primary screening clinical trials are presented herein. The presence of infectious organisms (candida, trichomonas, shift in bacterial flora, herpes, actinomyces) and BCC were noted in each of the clinical trial arms (current practice, CP; AutoPap-assisted practice, AP). For the purposes of these analyses, a report of infection or BCC from either arm was considered to be "truth." In 25,124 slides analyzed, there were 2,925 cases of infection identified. Of these, CP identified 2,141, and AP identified 1,985. The overall detection results are statistically equivalent. Of 17 cases of actinomyces, CP detected 8, while AP detected 12. Of 1,282 cases of candida, CP detected 983, and AP detected 865. Of 1,375 cases of shift of bacterial flora, CP detected 897, and AP detected 869. Of 14 cases of herpes, CP detected 9, and AP detected 11. Of 343 cases of trichomonas, CP detected 293, and AP detected 275. There were 5,156 cases of BCC identified in the trial. CP detected 3,431, and AP detected 3,276. The detection rates for BCC are statistically equivalent. The results show that the AutoPap-assisted practice for the primary screening of conventional cervical cytology slides is equivalent to the current practice for the detection of cervical infections and benign cellular changes.


Subject(s)
Image Cytometry , Image Interpretation, Computer-Assisted , Infections/pathology , Mass Screening/methods , Vaginal Smears , Actinomyces/isolation & purification , Animals , Candida/isolation & purification , Cervix Uteri/microbiology , Cervix Uteri/pathology , Evaluation Studies as Topic , Female , Humans , Infections/microbiology , Infections/parasitology , Infections/virology , Sensitivity and Specificity , Simplexvirus/isolation & purification , Trichomonas vaginalis/isolation & purification , Vagina/microbiology , Vagina/pathology
14.
Gynecol Oncol ; 74(2): 181-7, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10419729

ABSTRACT

Since the presence of precursors (pro-forms) of the aspartyl endoprotease, cathepsin D, appears to be linked with tumor progression, their presence was examined in sera and tumor tissues of ovarian cancer patients. The role of cathepsin D pro-forms was further assessed in the dysregulated proliferation and chemoresistance observed in advanced ovarian cancer. Cathepsin D was isolated from sera of ovarian cancer patients (n = 20) and normal volunteers (n = 11), as well as from solubilized normal ovarian epithelium (n = 8) and ovarian epithelial tumor tissue (n = 12). The specific molecular forms of cathepsin D were analyzed in these samples by Western immunoblot. Multiple circulating molecular weight forms of cathepsin D were identified in ovarian cancer patients ranging from 24 to 60 kDa, while in normal controls, a major band was observed at 34 kDa in all samples and minor bands corresponding to 27 and 48 kDa were detected in approximately half of the controls. To assess its consequences on ovarian cancer, the 52-kDa protein was immunoprecipitated from culture medium of an exponentially growing ovarian tumor cell line and was further purified by reverse-phase high-pressure liquid chromatography. Its effect on proliferation was assayed by determining cell doubling times and their chemosensitivity was measured in a standard cytotoxicity assay using cisplatin. In addition, decapeptides corresponding to the pro-portion of cathepsin D were analyzed in parallel. Procathepsin D and one decapeptide, peptide 2, as well as IGF-II (as a known positive) increased cell proliferation, with doubling times of 28.4, 28.8, and 30.3 h, respectively, versus untreated UL-1 cells (36.4 h). Procathepsin D treatment of UL-1 tumor cells significantly increased the cisplatin LD(50) (74.9 microgram/ml) over untreated (33.9 microgram/ml) as well as IGF-II-treated (38.8 microgram/ml) cells. Peptide 2 also showed a significant increase in LD(50) (69.5 microgram/ml) compared to untreated and peptide 1-treated cells (37.1 microgram/ml). There are several unique forms of cathepsin D expressed and accumulated by ovarian tumors and these forms are detectable in the sera of those with ovarian cancer. The presence of these procathepsin D can increase the proliferation of these tumor cells, while decreasing their sensitivity to chemotherapeutic agents. While procathepsin D and IGF-II both enhance proliferation, only procathepsin D (and peptide 2) appears to modulate chemosensitivity, suggesting a separate receptor or pathway for this consequence.


Subject(s)
Cathepsin D/physiology , Enzyme Precursors/physiology , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/pathology , Cathepsin D/biosynthesis , Cathepsin D/pharmacology , Cell Division/drug effects , Dose-Response Relationship, Drug , Drug Resistance, Neoplasm , Enzyme Precursors/biosynthesis , Enzyme Precursors/pharmacology , Female , Humans , Peptides/pharmacology , Peptides/physiology , Tumor Cells, Cultured
15.
Obstet Gynecol ; 93(4): 527-31, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10214827

ABSTRACT

OBJECTIVE: To determine whether small for gestational age (SGA) infants show changes in lipid metabolism that could distinguish growth-restricted subpopulations. METHODS: Sera from the arterial cord blood from 38 SGA infants were analyzed for apolipoprotein A-I level, total lipid content, and distribution of those lipids as triglycerides, diglycerides, free fatty acids, and phospholipids. Comparisons were made between appropriate for gestational age (AGA) controls (n = 25), SGA infants with a ponderal index below the tenth percentile (SGA I, n = 20), and SGA infants with a ponderal index above the tenth percentile (SGA II, n = 18). RESULTS: Total cord serum lipid content was markedly decreased in all SGA infants compared with AGA infants (2.8 times lower). Although SGA infants showed total lipid concentration decreases, SGA I and SGA II infants showed distinct characteristics. Infants in the SGA I group had higher triglyceride levels (1.8 times higher) and lower free fatty acid levels (1.4 times lower), compared with AGA infants (P < .001). The lipid subclass distribution in SGA II infants was not significantly different from that in AGA infants, with the exception of an increase in triglyceride concentrations (1.3 times higher). Although the 22-kD placenta-derived apolipoprotein A-I was similar in all groups, the level of fetal liver-derived 28-kD apolipoprotein A-I was 6.5 times lower in SGA I infants than in AGA or SGA II infants (P < .001). CONCLUSION: The SGA I infants appeared to have impaired utilization of circulating triglycerides, consistent with peripheral adipose depletion. Diminished fetus-derived apolipoprotein A-I levels with normal levels of placenta-derived apolipoprotein A-I levels might indicate a defect in the production or secretion of apolipoproteins associated with growth restriction.


Subject(s)
Fetal Blood/chemistry , Infant, Small for Gestational Age/blood , Lipids/blood , Humans , Infant, Newborn
16.
Int J Oncol ; 14(3): 515-21, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10024685

ABSTRACT

Expression of Bcl-2, Bax, p53 and induction of apoptosis were studied in cisplatin or Taxol treated monolayer and spheroid cultures of ovarian cancer cell lines (SKOV-3, UL-1, UL-3C). While cisplatin (15-75 microg/ml) induced apoptosis in monolayer and spheroid cultures, Taxol (100-800 nM) induced fragmentation in monolayers only. Cisplatin induced up to 5-fold DNA fragmentation in monolayers, while 3-fold (UL-3C, SKOV-3), and 1.5-fold (UL-1) in spheroids. Taxol treatment of monolayers resulted in the characteristic phosphorylation of Bcl-2, which was not demonstrated in spheroid cultures. Bax expression was reduced in spheroids following cisplatin or Taxol treatment, while p53 levels remained unchanged.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Ovarian Neoplasms/drug therapy , Paclitaxel/pharmacology , Proto-Oncogene Proteins c-bcl-2/metabolism , Spheroids, Cellular/drug effects , Antineoplastic Agents/pharmacology , Antineoplastic Agents, Phytogenic/pharmacokinetics , Apoptosis , Cisplatin/pharmacology , Female , Humans , Ovarian Neoplasms/metabolism , Paclitaxel/pharmacokinetics , Phosphorylation , Proto-Oncogene Proteins/biosynthesis , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Spheroids, Cellular/metabolism , Tumor Cells, Cultured , Tumor Suppressor Protein p53/biosynthesis , bcl-2-Associated X Protein
17.
J Soc Gynecol Investig ; 5(6): 334-8, 1998.
Article in English | MEDLINE | ID: mdl-9824816

ABSTRACT

OBJECTIVE: To determine the role of mifepristone (RU 486) in the growth of endometrial cancer cell lines, and the mechanism associated with this regulation. METHODS: Three endometrial cancer cell lines (Hec-1A, KLE, and RL95-2) were used in this study. Growth inhibition was demonstrated by sulforhodamine B cytotoxicity assay. Mode of inhibition by RU 486 was studied by induction of DNA fragmentation. The effect of RU 486 on steady-state accumulation of the progesterone and glucocorticoid receptors (PRs and GRs, respectively) and apoptosis-associated gene products was studied by Western blotting. RESULTS: We demonstrated a dose-dependent inhibition of growth in all of the three endometrial cancer cell lines. Following treatment with 5.0 micrograms/mL of RU 486, there was 39.3%, 66.3%, and 75.5% inhibition of KLE, Hec-1A, and RL95-2 cells, respectively. Decreased expression of GR in RL95-2 (0.1-10 micrograms/mL) and in KLE cells (10 micrograms/mL) was observed. A marked decrease of PR was seen with RL95-2 cells at 10 micrograms/mL, there was no change in the KLE cells, and a dose-dependent decrease was seen with Hec-1A cells. Various levels of apoptosis were demonstrated by DNA fragmentation in all three cell lines. Of the genes associated with apoptosis, dose-dependent reduction of bax expression was demonstrated in KLE cells, while induction of WAF-1 was seen in Hec-1A and RL95-2 cells, and reduction of bcl-2 was demonstrated in RL95-2 cells. CONCLUSION: Clinically achievable doses of RU 486 inhibit endometrial cancer cell lines. The mechanism of inhibition involves apoptosis, and regulation of bax, bcl-2, and WAF-1 is demonstrated. Therapeutic application of these findings remains to be determined.


Subject(s)
Endometrial Neoplasms/drug therapy , Hormone Antagonists/therapeutic use , Mifepristone/therapeutic use , Proto-Oncogene Proteins c-bcl-2 , Apoptosis/genetics , Cell Division/drug effects , DNA Fragmentation , Endometrial Neoplasms/metabolism , Endometrial Neoplasms/pathology , Female , Humans , Progesterone/antagonists & inhibitors , Proto-Oncogene Proteins/metabolism , Receptors, Glucocorticoid/metabolism , Receptors, Progesterone/metabolism , Tumor Cells, Cultured , bcl-2-Associated X Protein
18.
Oncol Rep ; 5(6): 1519-24, 1998.
Article in English | MEDLINE | ID: mdl-9769398

ABSTRACT

Inhibition of the immune system has been observed in association with most stages of ovarian cancer; however, the mechanisms involved in the induction and maintenance of this chronic immune unresponsiveness associated with cancer progression are poorly understood. This immunosuppressed state is primarily defined as the failure to eradicate the tumor. This immunosuppressed state is generally associated with decreased numbers and reactivity of lymphoid cells in women with ovarian cancer. The degree of immune dysfunction in ovarian cancer patients has been demonstrated to correlate with patient survival. While ovarian cancer patients generally fail to exhibit effective immunosurveillance, as manifested by continued tumor growth and progression, the presence of tumor-reactive immunoglobulins can be demonstrated in these women, indicating the continued presence of immune recognition. We have not only demonstrated the presence of tumor-reactive antibodies in ovarian cancer patients, but have also shown that the levels of these antibodies increase as the disease progresses. The antigens recognized by the patients' humoral response have been identified as either membrane-associated or intra-cellular. In general, the localization of these antigens tend to be linked to the patient's prognosis. The presence of a humoral response against intracellular proteins are correlated with poor prognosis, while autoantibodies reactive with surface components appear to have a better prognosis. In addition to general antigen recognition, these reactive antibodies have been utilized to define specific epitopes on tumor-associated proteins. Certain specific antigenic epitopes exhibit common recognition among patients with the same tumor type. The specific recognition of certain epitopes can provide early evidence of aberrant protein expression and this aberrant expression of certain proteins, such as procathepsin D, appear to be linked to the tumor's acquisition of specific malignant characteristics, including metastasis formation and chemoresistance. Despite the existence of circulating tumor-reactive immunoglobulins, their presence correlates, in general, with poor prognosis and poor host survival. Since tumor-reactive immunoglobulins are elicited and can be detected early in the development of tumors and their enhanced synthesis is induced prior to the clinical manifestation of recurrence, the assessment of the tumor-reactive immune response against specific antigenic epitopes should represent an early significant diagnostic and prognostic marker in ovarian cancer.


Subject(s)
Antibodies, Neoplasm/analysis , Ovarian Neoplasms/immunology , Antibody Formation , Antigens, Neoplasm/analysis , Antigens, Neoplasm/immunology , Disease Progression , Epitopes/analysis , Female , Humans , Immunity, Cellular , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/pathology , Ovarian Neoplasms/therapy , Prognosis
19.
Gynecol Oncol ; 70(1): 33-9, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9698470

ABSTRACT

OBJECTIVE: The risk of developing endometrial cancer is reduced with increasing parity. The purpose of this study was to investigate the possibility that maternal immunization against fetal antigens might be elicited during pregnancy and, if so, to characterize antigens reactive with this immune response. METHODS: Sera were obtained from nulliparous (n = 9) and multiparous women (n = 14). Cellular proteins were isolated from normal endometrium and cultured cells from early (HEC-1A) and late (KLE and RL95-2) stage endometrial cancers. These were separated by SDS-PAGE and those proteins reactive with each individual's serum were assessed by Western immunoblot. Reactive proteins were isolated from KLE tumor cells by immunoaffinity columns. Three commonly recognized proteins were identified, separated, and processed for internal microsequencing. RESULTS: Sera from multiparous women, used as primary antibodies, recognized multiple bands on endometrial tumors, ranging from 10 to 120 kDa. Several antigens were commonly recognized by the sera of multiparous women. The three commonly recognized proteins, normally expressed by fetal tissues, were identified as cystatin A (10 kDa), epidermal fatty acid binding protein (18 kDa), and keratin 10 (54 kDa). Nulliparous women failed to recognize these antigens. CONCLUSION: These findings suggest that certain antigens expressed by the fetus and/or the placenta immunize women during pregnancy. This immune response may protect these women from developing endometrial cancer and explain epidemiologic findings. Future studies will explore the utility of these reexpressed fetal antigens as possible targets for active immunotherapy.


Subject(s)
Antigens, Neoplasm/immunology , Endometrial Neoplasms/immunology , Parity/immunology , Pregnancy/immunology , Adult , Antigens, Neoplasm/isolation & purification , Female , Humans , Pregnancy/blood
20.
Am J Reprod Immunol ; 39(6): 368-75, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9645267

ABSTRACT

PROBLEM: The possible link between p53-reactive antibodies in multiparous women and exposure to a unique p53 protein during pregnancy was examined. METHOD OF STUDY: p53-reactive antibodies were evaluated in sera from nulligravid and multiparous women and patients with ovarian cancer by Western immunoblot. Furthermore, the presence of p53 protein was assayed in cord blood by enzyme-linked immunosorbent assay. Cord blood-derived p53 was compared structurally by protein fingerprinting and functionally by gel mobility shift assay to other isolates of p53. RESULTS: Antibodies reactive with wild-type p53 were observed in 92% of multiparous women and 42% were reactive with one tumor-derived p53 protein. p53 protein was detected in 27 of 154 samples of cord blood. Structural analysis indicated that the fetal p53 resembled the UL-1 p53. Functionally, the fetal and UL-1 protein failed to bind DNA. CONCLUSIONS: Fetal p53 protein seems to be distinct from wild-type p53, characterized by enhanced stability, structural differences and inability to bind DNA, analogous to alternatively spliced variants. Exposure to fetal p53 protein may form the basis for immunologic protection against cancer induced by multiparity.


Subject(s)
Autoantibodies/blood , Fetal Blood/chemistry , Fetal Blood/immunology , Maternal-Fetal Exchange/immunology , Tumor Suppressor Protein p53/blood , Tumor Suppressor Protein p53/immunology , Antibodies, Monoclonal , Female , Fetus/immunology , Humans , Immunization , Infant, Newborn , Mutation , Ovarian Neoplasms/etiology , Ovarian Neoplasms/immunology , Ovarian Neoplasms/prevention & control , Parity/immunology , Placenta/immunology , Pregnancy , Tumor Suppressor Protein p53/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...